MedTrace Logo

Non-invasive Tumor Immunoglobulin Gene Next Generation Sequencing (IgNGS) in Diffuse Large B Cell Lymphoma (DLBCL)

NCT04237168 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2020-01-29

No results posted yet for this study

Summary

This study will evaluate IgNGS at different time points in newly diagnosed DLBCL patients homogeneously treated (RCHOP) to address its correlation with conventional techniques (i.e., positron emission tomography/computed tomography imaging (PET/CT) and outcome.

Conditions

  • Lymphoma, Large B-Cell, Diffuse

Interventions

DIAGNOSTIC_TEST

IgNGS from circulating tumor DNA

3 longitudinal plasma samples will be evaluated at three different time points per patient: 0 (pre-treatment), end of treatment, and at 6 months after treatment.

Sponsors & Collaborators

  • Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

    lead OTHER

Principal Investigators

  • Javier Briones · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-31
Primary Completion
2021-12-31
Completion
2022-07-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04237168 on ClinicalTrials.gov